GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
It seems obvious that RM’s heart’s not in the home trial - yet.
The hospital setting is where the premium price potentially is, so go for that first. However, in the eyes of the medical world, that may consign SNG001 towards the moderate/severe treatment end of the spectrum, allowing other treatments to gain entry earlier on. And bear in mind that cheap old stuff like dexamethasone is waiting for them as standard care now.
In the community, contemplating charging £2k for a treatment comprising a naturally occurring protein in an inhaler/nebuliser, in patient population inbthe millions, perhaps, imho won’t fly.
A government contract for Covid may soak up the cost initially, but longer term (for COPD/Asthma) the price may need to drop a zero...
Oakleaf72,
Of course I hope you’re right. But from experience I can tell you that obtaining reimbursement (ok, under normal circumstances) either by the NHS via NICE, or in other European healthcare systems, would tie up a small team for weeks - and Synairgen simply don’t have the infrastructure to do it.
The US would be a separate case and their Managed Care system would need to be negotiated, possibly on a State- by- State basis. There’s no way on Earth Synairgen could cope with that.
Lastly, I doubt it will be up to Synairgen to ultimately choose a brand name!
Imho Synairgen’s top priority is to appoint/agree a JV Partner.
Without one, there’s a danger they’ll get in over their heads as they have no capacity to take this to market on their own.
They may suggest a value for SNG001 but will have little influence on what the NHS pays or indeed, other governments should the (so far unnamed) drug be successful.
Imho Synairgen’s top priority is to appoint/agree a JV Partner.
Without one, there’s a danger they’ll get in over their heads as they have no capacity to take this to market on their own.
They may suggest a value for SNG001 but will have little influence on what the NHS pays or indeed, other governments should the (so far unnamed) drug be successful.
£2k per treatment is way out of kilter imho. They need to get the price down - or stop talking about it, if true.
Such a price may be good for shareholders(of which i’m a lth) but will not appeal to the NHS.
Anyway, Synairgen will not be responsible for the marketing of the product, so RM should keep quiet.
The impression I get is that their online business is continuing to compensate for declining high st/retail park sales.
Certainly, I’d expect them to keep taking mkt share from John Lewis and others in a very fragmented market.
For those interested, anti-viral nasal sprays are already available on Amazon and Boots.
https://www.mirror.co.uk/science/coronavirus-scientists-develop-7pday-nasal-23052724
Suggests they’ve had a good 4th quarter.
For those who are concerned, is this not a question that the company can be asked directly?
As in ‘Do you intend to issue an RNS announcement when dosing of patients within the Phase 3 trial of SNG001 begins?’
Presumably they will answer ‘yes’ or ‘no’.
Docdaneeka,
Very much agree, which is why recruitment for the home trial has appeared half-hearted.
But I also feel that treatment with SNG001 could be usefully adopted in care homes/ nursing homes in an attempt to intercept the disease prior to hospitalisation.
Both locations should have staff qualified to identify the condition and the skill to ensure the drug was administered correctly in a particularly vulnerable section of the population.
Imho the less RM talks about the cost of treatment for SNG001, the better.
Synairgen has no capacity to market the drug, so the question of price is best left to any JV partner.
In addition, he needs to get the product positioned clearly in the marketplace.
3k (£ or $) for a home treatment is ludicrous.